Michael Saulino, MD
Physical Medicine & Rehabilitation · Elkins Park, PANPI 1821178484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $323,720 of the $424,513 with a category attached, or 76.3%. Ipsen Biopharmaceuticals, Inc accounts for 85.2% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $100,141, 4.4 times the $22,535 reported in 2019. Among physical medicine & rehabilitation clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $1082.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$362K
- Medtronic$27K
- Tersera Therapeutics LLC$9K
- AbbVie$8K
- Piramal Critical Care$6K
- SPR Therapeutics, Inc$4K
- plus $8K from 15 others
Across 51 payments — averaging $1517.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$56K
- Medtronic$18K
- Pacira Pharmaceuticals Incorporated$3K
What the payments were for
- Consulting fees$49,03012%
- Speaking & faculty fees$323,72076%
- Travel & lodging$37,1909%
- Food & beverage$14,5733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 212 | $361,749 |
| Medtronic(2 entities) | 66 | $27,162 |
| Tersera Therapeutics LLC | 29 | $8,772 |
| AbbVie(2 entities) | 25 | $8,050 |
| Piramal Critical Care | 13 | $6,191 |
| SPR Therapeutics, Inc | 4 | $4,369 |
| Pacira Pharmaceuticals Incorporated | 18 | $4,037 |
| Amneal Pharmaceuticals LLC | 4 | $2,826 |
| Sandoz | 1 | $477 |
| Merz Pharmaceuticals, LLC | 4 | $373 |
| Saol Therapeutics Inc. | 2 | $96 |
| Globus Medical | 1 | $58 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Stimwave Technologies Incorporated | 1 | $56 |
| Nalu Medical, Inc. | 1 | $53 |
| GRT US Holding, Inc. | 1 | $50 |
| CSL Behring | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Flowonix Medical Incorporated | 1 | $26 |
| UCB, Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$359,146
- GABLOFEN$15,502
- SYNCHROMED$13,361
- PRIALT$8,721
- BOTOX$6,605
- LIORESAL$6,262
- SYNCHROMEDII$4,813
- SPRINT PNS System$4,200
- GABLOFEN 1 mL in 1 SYRINGE, GLASS$2,940
- EXPAREL$2,696
- LYVISPAH$2,600
- Zilretta$943
- Iovera$525
- INTELLIS ADAPTIVESTIM$355
- XEOMIN$254
- PERCEPT PC BRAINSENSE$251
- VANTA ADAPTIVESTIM$134
- INTELLIS$133
- INCEPTIV$113
How this compares
$424,513 in reported general payments places this provider in the 95th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
See all physical medicine & rehabilitation providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 83 | $122,662 |
| Oxycodone Hcl | 268 | $10,523 |
| Morphine Sulfate ErMorphine Sulfate | 70 | $9,160 |
| Hydromorphone Hcl | 41 | $3,282 |
| Lidocaine | 14 | $2,927 |
| Gabapentin | 118 | $2,641 |
| Morphine Sulfate | 35 | $2,227 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 75 | $2,206 |
| Baclofen | 44 | $1,618 |
| Methadone Hcl | 33 | $1,536 |
| Naloxone Hcl | 22 | $1,381 |
| Tizanidine Hcl | 67 | $960 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $934 |
| Pregabalin | 54 | $738 |
| Diazepam | 64 | $709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $2,826 | $11514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
Other physical medicine & rehabilitation in Elkins Park
- Leonard KamenElkins Park$44K
- Daniel MoonElkins Park$7K
- Jeffery RoweKing Of Prussia$1.9M
- Huaguang QuChalfont$356K
- Alberto EsquenaziPhiladelphia$305K
- Mitchell PaulinPaoli$229K
- Kimberly HeckertPhiladelphia$119K
- David LichtenReading$117K
- Gay WilcherRidley Park$81K
- Jessica MulhernPaoli$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.